Health and Fitness Health and Fitness
Wed, May 19, 2010
[ 01:05 PM ] - Market Wire
Conceptus® to Present at Two Investor Health Care Conferences in June
[ 01:01 PM ] - Market Wire
Emeritus Announces Lease Acquisition of Four Senior Living Communities
[ 01:00 PM ] - Market Wire
Data Suggest Denufosol May Hold Promise as an Early Intervention Treatment for Cystic Fibrosis
[ 01:00 PM ] - Market Wire
SurModics Receives ISO Certification at SurModics Pharmaceuticals Facilities
[ 12:50 PM ] - Market Wire
Teva Announces Launch and Shipment of Generic Lipitor® Tablets in Canada
[ 12:24 PM ] - Market Wire
AGA Medical to Present at the Citi Investment Res .. rch Global Health Care Conference on May 27, 2010
[ 11:08 AM ] - Market Wire
Diagnostic Imaging International Corp. Second Quarter Results 2010
[ 11:05 AM ] - Market Wire
Aetna Announces Appearance at 2010 Citi Investment Research Global Health Care Conference
[ 10:48 AM ] - Market Wire
Medical Facilities Corporation announces May distribution
[ 10:35 AM ] - Market Wire
Allergan Receives FDA Approval for ZYMAXIDa" Ophthalmic Solution
[ 10:00 AM ] - Market Wire
Geophysics Completed at Fortune River's Highland Project, Drilling Planned for July
[ 08:30 AM ] - Market Wire
XTend Medical Corporation (XMDC) Files Complaint in Delaware Chancery Court
[ 08:28 AM ] - Market Wire
High Desert Gold Reports Strong Initial Explorati .. sults at San Antonio Gold Project, Sonora, Mexico
[ 08:23 AM ] - Market Wire
Vatican Endorsement Seals NBS's Status as the Major Play in Regenerative Medicine
[ 08:00 AM ] - Market Wire
First Patient Treated with Valiant® Thoracic Stent Graft in Medtronic's ''RESCUE'' Clinical Study
[ 07:00 AM ] - Market Wire
Hypertension Diagnostics Announces FY 2010 Third Quarter Results
[ 07:00 AM ] - Market Wire
Enzo Biochema?s Clinical Labs Unit Enters into Co .. ystems, Inc., for Web-Based Medical Records and P
[ 07:00 AM ] - Market Wire
Alexion to Present at the Citi 2010 Global Health Care Conference
[ 06:27 AM ] - Market Wire
SecureAlert, Inc. Announces Positive Stockholders' Equity and Gross Profit Margin Increase
[ 06:00 AM ] - Market Wire
European Patent Office Appeal Board Rules in Favor of Alnylama?s Kreutzer-Limmer Patent
[ 05:57 AM ] - Market Wire
Covidien???????????? SILSa" ?????
[ 05:55 AM ] - Market Wire
Targacept Initiates Phase 2 Study of TC-5619 in Attention Deficit/Hyperactivity Disorder in Adults
[ 05:30 AM ] - Market Wire
Cerus Appoints William "Obi" Greenman as Chief Business Officer
[ 05:30 AM ] - Market Wire
Data on VIVITROL® to be Presented at Upcoming American Psychiatric Association Annual Meeting
[ 05:30 AM ] - Market Wire
Vicor Technologies Announces Results of PD2i(R) Analysis of MUSIC Trial Data
[ 05:00 AM ] - Market Wire
Curis Added to NASDAQ Biotechnology Index
[ 04:30 AM ] - Market Wire
Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
[ 04:30 AM ] - Market Wire
Geron Announces Positive Data on Its Small Molecu .. tivator in Model of Idiopathic Pulmonary Fibrosis
[ 04:08 AM ] - Market Wire
Roche en Biogen Idec maken bekend te stoppen met .. r ocrelizumab bij patinten met reumatode artritis
[ 04:05 AM ] - Market Wire
Roche y Biogen Idec interrumpen el programa de de .. ocrelizumab en pacientes con artritis reumatoide

Roche y Biogen Idec interrumpen el programa de desarrollo clnico de ocrelizumab en pacientes con artritis reumatoide


Published on 2010-05-19 04:11:17 - Market Wire
  Print publication without navigation


BASILEA, Suiza & CAMBRIDGE, Massachussets--([ BUSINESS WIRE ])--Roche (SIX: RO, ROG; OTCQX: RHHBY) y Biogen Idec (NASDAQ: BIIB) han anunciado hoy su decisin de interrumpir el programa de desarrollo clnico de ocrelizumab en pacientes con artritis reumatoide(AR).

Tras un anlisis detallado de los resultados de eficacia y seguridad del programa AR, las empresas han llegado a la conclusin de que el beneficio global del perfil de riesgo de ocrelizumab no era favorable en AR, teniendo en cuenta las opciones de tratamiento disponibles en la actualidad.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources